HCPCS Level II · Drugs administered other than oral method
J0578Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J0578
J0578 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy.
It was added to HCPCS effective 04/01/2024.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj brixadi, more than 7 day
- Date added
- 04/01/2024
- Action effective
- 04/01/2024
- BETOS
- O1E
Related J05xx codes
- J0500Injection, dicyclomine hcl, up to 20 mg
- J0515Injection, benztropine mesylate, per 1 mg
- J0517Injection, benralizumab, 1 mg
- J0520Injection, bethanechol chloride, myotonachol or urecholine, up to 5 mg
- J0525Injection, cefotetan disodium, 10 mg
- J0528Injection, fosfomycin disodium, 20 mg
- J0558Injection, penicillin g benzathine and penicillin g procaine, 100,000 units
- J0561Injection, penicillin g benzathine, 100,000 units
- J0565Injection, bezlotoxumab, 10 mg
- J0567Injection, cerliponase alfa, 1 mg
- J0570Buprenorphine implant, 74.2 mg
- J0571Buprenorphine, oral, 1 mg
Common questions about J0578
Is HCPCS J0578 still valid?
- Yes. J0578 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J0578?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.